4R-Tau Targeting Therapies for PSP and CBS

🧫 Experiment Protocol ClinicalAlzheimer's DiseasePSPhumanproposed

# 4R-Tau Targeting Therapies for PSP and CBS ## Background and Rationale This Phase II randomized, double-blind, placebo-controlled clinical trial investigates isoform-selective 4R-tau targeting therapies for Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS). These primary 4R-tauopathies represent distinct pathological entities from Alzheimer's disease, characterized by selective aggregation of four-repeat tau isoforms in neurons and glia. The pathological hallmark involves microtubule-binding repeat domains that confer unique structural properties, making 4R-tau aggregates more resistant to conventional tau-targeting approaches designed for mixed 3R/4R pathology. The study employs a novel anti-4R-tau monoclonal antibody (mAb-4RT) engineered with enhanced blood-brain barrier penetration and selective binding to pathological 4R conformations. The therapeutic mechanism involves facilitated clearance through microglial phagocytosis and prevention of trans-synaptic propagation. Primary endpoints include clinical progression measured by PSP Rating Scale and CBS Functional Rating Scale, alongside biomarker assessment through CSF 4R-tau species quantification using mass spectrometry. Secondary measures encompass neuroimaging markers including midbrain atrophy rates via volumetric MRI and 18F-flortaucipir PET tau burden quantification. The study design incorporates stratified randomization based on disease duration, genetic risk factors (MAPT H1/H2 haplotype), and baseline clinical severity. This represents the first clinical validation of isoform-selective tau therapeutics, potentially establishing precision medicine approaches for distinct tauopathy subtypes. Innovation includes development of conformational-specific biomarkers, implementation of adaptive trial design with interim efficacy analysis, and integration of pharmacokinetic modeling to optimize dosing regimens. Success would validate the 4R-tau selective targeting hypothesis and provide clinical proof-of-concept for differentiated therapeutic approaches across the tauopathy spectrum. This experiment directly tests predictions arising from the following hypotheses: - **Noradrenergic-Tau Propagation Blockade** - **HSP90-Tau Disaggregation Complex Enhancement** - **Tau-Independent Microtubule Stabilization via MAP6 Enhancement** - **Synaptic Vesicle Tau Capture Inhibition** - **LRP1-Dependent Tau Uptake Disruption** ## Experimental Protocol Phase 1 (Weeks 0-4): Screen 300 participants with probable PSP (MDS-PSP criteria) or CBS (Armstrong criteria) aged 40-80. Conduct comprehensive baseline assessments including neuropsychological batteries, movement disorder scales, volumetric brain MRI, and lumbar puncture for CSF biomarkers. Randomize 180 eligible participants 2:1 to mAb-4RT (15 mg/kg IV monthly) versus placebo. Phase 2 (Weeks 4-52): Administer monthly infusions with safety monitoring including vital signs, laboratory assessments, and immunogenicity panels. Conduct clinical evaluations every 8 weeks using PSP Rating Scale, CBS Functional Rating Scale, and Schwab-England Activities of Daily Living. Perform CSF sampling at weeks 12, 24, and 48 for 4R-tau quantification via liquid chromatography-tandem mass spectrometry. Phase 3 (Weeks 24, 48): Execute neuroimaging assessments including structural MRI for volumetric analysis of midbrain, superior cerebellar peduncle, and cortical regions using FreeSurfer processing. Conduct 18F-flortaucipir PET imaging with standardized uptake value ratio quantification in predefined regions of interest. Phase 4 (Week 52-64): Complete final assessments and initiate 12-week safety follow-up period. Primary analysis employs mixed-effects models accounting for repeated measures, baseline covariates, and stratification factors. Sample size calculation assumes 40% reduction in clinical progression rate with 80% power and alpha=0.05. ## Expected Outcomes - 1. Clinical progression rate reduction of 35-40% in mAb-4RT group compared to placebo, measured by composite PSP/CBS functional scales (effect size d=0.6, p<0.01) - 2. CSF 4R-tau oligomer levels decrease by 50-65% from baseline in treatment group versus 10% increase in placebo group by week 48 - 3. Midbrain atrophy rate reduction of 30-40% in treated participants, with annual volume loss decreasing from 8-10% to 5-6% (p<0.05) - 4. 18F-flortaucipir PET signal reduction of 20-25% in target brain regions (midbrain, basal ganglia, cortical areas) in treatment versus control groups - 5. Treatment-related adverse events occurring in <15% of participants, with infusion reactions as most common side effect (<8% incidence) - 6. Plasma pharmacokinetics demonstrating CNS penetration with CSF/plasma ratio >0.3% and sustained target engagement >75% between doses ## Success Criteria - • Primary efficacy endpoint: ≥30% reduction in clinical progression rate with p-value <0.05 and confidence interval excluding null hypothesis - • Biomarker validation: ≥40% reduction in CSF 4R-tau pathological species with correlation coefficient >0.5 to clinical measures - • Neuroimaging outcomes: Statistically significant reduction in brain atrophy rates (p<0.05) in ≥2 prespecified regions of interest - • Safety profile: <20% treatment discontinuation rate due to adverse events with no drug-related serious adverse events - • Target engagement: Demonstration of >70% sustained 4R-tau binding occupancy throughout dosing interval via PET tracer studies - • Pharmacokinetic success: Achievement of therapeutic CSF concentrations (>1 μg/mL) in >80% of participants with acceptable half-life (>72 hours)

Source: wiki

🧫 Experiment Extras

🔴 Alzheimer's Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found